Tactile Systems Technology (NASDAQ:TCMD) Cut to "Buy" at StockNews.com

StockNews.com downgraded shares of Tactile Systems Technology (NASDAQ:TCMD - Free Report) from a strong-buy rating to a buy rating in a report released on Saturday morning.

Separately, B. Riley lowered shares of Tactile Systems Technology from a "buy" rating to a "neutral" rating and decreased their price target for the company from $23.00 to $18.00 in a research report on Wednesday, February 19th.

Tactile Systems Technology Trading Up 1.9 %

Shares of TCMD traded up $0.26 during mid-day trading on Friday, reaching $13.86. 142,996 shares of the company's stock traded hands, compared to its average volume of 248,138. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.36 and a quick ratio of 3.80. The stock's 50-day moving average is $15.25 and its two-hundred day moving average is $15.81. Tactile Systems Technology has a 12 month low of $11.12 and a 12 month high of $21.10. The stock has a market cap of $328.01 million, a P/E ratio of 19.80 and a beta of 1.20.

Tactile Systems Technology (NASDAQ:TCMD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.09. Tactile Systems Technology had a net margin of 5.79% and a return on equity of 9.37%. The firm had revenue of $85.59 million during the quarter, compared to the consensus estimate of $85.39 million. Research analysts forecast that Tactile Systems Technology will post 0.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Daniel L. Reuvers sold 10,938 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $14.55, for a total value of $159,147.90. Following the completion of the transaction, the director now directly owns 242,942 shares of the company's stock, valued at approximately $3,534,806.10. This represents a 4.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Kristie Burns sold 4,830 shares of the firm's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $14.65, for a total transaction of $70,759.50. Following the completion of the transaction, the vice president now directly owns 84,008 shares in the company, valued at approximately $1,230,717.20. This represents a 5.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 19,546 shares of company stock valued at $285,444. 0.96% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Jones Financial Companies Lllp acquired a new position in Tactile Systems Technology in the fourth quarter valued at approximately $39,000. Virtus Fund Advisers LLC lifted its position in Tactile Systems Technology by 142.0% in the fourth quarter. Virtus Fund Advisers LLC now owns 4,199 shares of the company's stock valued at $72,000 after buying an additional 2,464 shares during the last quarter. Quarry LP purchased a new position in Tactile Systems Technology during the fourth quarter worth about $81,000. 1620 Investment Advisors Inc. acquired a new stake in shares of Tactile Systems Technology during the fourth quarter valued at about $97,000. Finally, Legal & General Group Plc raised its stake in shares of Tactile Systems Technology by 33.2% in the 4th quarter. Legal & General Group Plc now owns 6,257 shares of the company's stock valued at $107,000 after acquiring an additional 1,558 shares during the period. Hedge funds and other institutional investors own 83.43% of the company's stock.

Tactile Systems Technology Company Profile

Tactile Systems Technology, Inc, a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema in the home setting; and Entre Plus System, a portable pneumatic compression device for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers.